[Pharmacotherapy after cardiac infarction]

Internist (Berl). 2001 May;42(5):699-712. doi: 10.1007/s001080050811.

[Article in German]

Authors

H Darius¹, J Meyer

Affiliation

¹ II. Medizinische Klinik & Poliklinik, Johannes Gutenberg-Universität, Langenbeckstrasse 1, 55101 Mainz. [email protected]

PMID: 11400577
DOI: 10.1007/s001080050811

No abstract available

Publication types

Review

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Anticoagulants / therapeutic use*
Arteriosclerosis / complications
Fibrinolytic Agents / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Myocardial Infarction / drug therapy*
Myocardial Infarction / etiology
Myocardial Infarction / prevention & control
Randomized Controlled Trials as Topic
Risk Factors
Secondary Prevention
Time Factors

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Anticoagulants
Fibrinolytic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors